357 related articles for article (PubMed ID: 38628644)
1. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.
Jiang S; Han S; Wang DW
Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644
[TBL] [Abstract][Full Text] [Related]
2. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
3. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase: gene structure, expression and deletion.
Harris TR; Hammock BD
Gene; 2013 Sep; 526(2):61-74. PubMed ID: 23701967
[TBL] [Abstract][Full Text] [Related]
5. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
6. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
7. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
Wang Q; Huo L; He J; Ding W; Su H; Tian D; Welch C; Hammock BD; Ai D; Zhu Y
Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1894-903. PubMed ID: 26453326
[TBL] [Abstract][Full Text] [Related]
8. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system.
Kuo YM; Lee YH
Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
[TBL] [Abstract][Full Text] [Related]
10. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
11. ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW).
Papiashvili N; Gongadze N; Bakuridze A; Bakuridze K
Georgian Med News; 2021 Mar; (312):125-132. PubMed ID: 33964840
[TBL] [Abstract][Full Text] [Related]
12. [Soluble epoxide hydrolase and lipid metabolism].
Ma XX; Liu Y; Zhu Y
Sheng Li Ke Xue Jin Zhan; 2010 Aug; 41(4):267-71. PubMed ID: 21416942
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
[TBL] [Abstract][Full Text] [Related]
14. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
16. Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Zhao C; Jiang X; Peng L; Zhang Y; Li H; Zhang Q; Wang Y; Yang F; Wu J; Wen Z; He Z; Shen J; Chen C; Wang DW
J Mol Cell Cardiol; 2023 Dec; 185():13-25. PubMed ID: 37871528
[TBL] [Abstract][Full Text] [Related]
17. Inside epoxyeicosatrienoic acids and cardiovascular disease.
Tacconelli S; Patrignani P
Front Pharmacol; 2014; 5():239. PubMed ID: 25426071
[TBL] [Abstract][Full Text] [Related]
18. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
19. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase: A potential target for metabolic diseases.
He J; Wang C; Zhu Y; Ai D
J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
